Market Overview

UPDATE: Goldman Sachs Raises PT on Stryker Corporation on Completed Acquisition, Updated Model

Related SYK
Benzinga's Top Downgrades
Goldman Remains Constructive on MedTech, Sees 'New Opportunities' Amid Selloff

In a report published Monday, Goldman Sachs reiterated its Buy rating on Stryker Corporation (NYSE: SYK), and slightly raised its price target from $71.00 to $72.00.

Goldman Sachs noted, “We update our model for the completed acquisition of Trauson Holdings and the announced $250mn ASR. Trauson is an orthopaedic device manufacturer headquartered in China with a primary focus on trauma and spine (77% of sales combined). 2012 revenue was around $75-80 million, growing at 25-30%. Stryker management indicated the transaction to be neutral to 2013E EPS and accretive thereafter. We believe there could be further upside to estimates should Stryker prove successful at leveraging Trauson's existing channels in China to sell a broader product suite.”

Stryker Corporation closed on Friday at $64.90.

Latest Ratings for SYK

Sep 2015NeedhamDowngradesBuyHold
Aug 2015Stifel NicolausMaintainsBuy
Aug 2015Credit SuisseAssumesOutperform

View More Analyst Ratings for SYK
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings


Related Articles (SYK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters